Abstract
Congenital or hereditary myasthenia describes a heterogeneous group of disorders in which the immune system is not implicated. Treatment has previously depended on anticholinesterase medication. The effectiveness of 3,4-diaminopyridine (3,4-DAP), a preparation that enhances acetylcholine release from motor nerve terminals, has been evaluated using a series of standardised strength measures. Sixteen patients (aged seven to 47 years) were studied in an open prospective trial, and four of them in a double blind crossover trial; existing anticholinesterase medication was continued. For the group as a whole, there was a highly significant increase in muscle strength (p less than 0.001; n = 16). In individual paired comparisons, 13 out of 16 showed significant improvement in the open trial and four out of four in the blind crossover trial. In conclusion, 3,4-DAP, either alone or combined with anticholinesterase medication, may be a useful additional treatment in congenital myasthenia.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Engel A. G., Lambert E. H., Mulder D. M., Torres C. F., Sahashi K., Bertorini T. E., Whitaker J. N. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol. 1982 Jun;11(6):553–569. doi: 10.1002/ana.410110603. [DOI] [PubMed] [Google Scholar]
- Harvey A. L., Marshall I. G. The actions of three diaminopyridines on the chick biventer cervicis muscle. Eur J Pharmacol. 1977 Aug 15;44(4):303–309. doi: 10.1016/0014-2999(77)90303-x. [DOI] [PubMed] [Google Scholar]
- Kirsch G. E., Narahashi T. 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys J. 1978 Jun;22(3):507–512. doi: 10.1016/S0006-3495(78)85503-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McEvoy K. M., Windebank A. J., Daube J. R., Low P. A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989 Dec 7;321(23):1567–1571. doi: 10.1056/NEJM198912073212303. [DOI] [PubMed] [Google Scholar]
- Mora M., Lambert E. H., Engel A. G. Synaptic vesicle abnormality in familial infantile myasthenia. Neurology. 1987 Feb;37(2):206–214. doi: 10.1212/wnl.37.2.206. [DOI] [PubMed] [Google Scholar]
- Murray N. M., Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology. 1981 Mar;31(3):265–271. doi: 10.1212/wnl.31.3.265. [DOI] [PubMed] [Google Scholar]
- Oosterhuis H. J., Newsom-Davis J., Wokke J. H., Molenaar P. C., Weerden T. V., Oen B. S., Jennekens F. G., Veldman H., Vincent A., Wray D. W. The slow channel syndrome. Two new cases. Brain. 1987 Aug;110(Pt 4):1061–1079. doi: 10.1093/brain/110.4.1061. [DOI] [PubMed] [Google Scholar]
- Vincent A., Cull-Candy S. G., Newsom-Davis J., Trautmann A., Molenaar P. C., Polak R. L. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases. Muscle Nerve. 1981 Jul-Aug;4(4):306–318. doi: 10.1002/mus.880040407. [DOI] [PubMed] [Google Scholar]
- Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985 Dec;48(12):1246–1252. doi: 10.1136/jnnp.48.12.1246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wiles C. M., Karni Y., Nicklin J. Laboratory testing of muscle function in the management of neuromuscular disease. J Neurol Neurosurg Psychiatry. 1990 May;53(5):384–387. doi: 10.1136/jnnp.53.5.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Donselaar C. A., Geerts A. T., Meulstee J., Habbema J. D., Staal A. Reliability of the diagnosis of a first seizure. Neurology. 1989 Feb;39(2 Pt 1):267–271. doi: 10.1212/wnl.39.2.267. [DOI] [PubMed] [Google Scholar]